IFN-α induces a preferential long-lasting expression of MHC class I in human pancreatic beta cells

被引:49
作者
de Brachene, Alexandra Coomans [1 ]
Dos Santos, Reinaldo S. [1 ]
Marroqui, Laura [1 ,2 ,3 ]
Colli, Maikel L. [1 ]
Marselli, Lorella [4 ]
Mirmira, Raghavendra G. [5 ]
Marchetti, Piero [4 ]
Eizirik, Decio L. [1 ]
机构
[1] Univ Libre Bruxelles, Med Fac, ULB Ctr Diabet Res, Campus Erasme,Route Lennik,808-CP618, B-1070 Brussels, Belgium
[2] Miguel Hernandez Univ Elche, CIBER Diabet & Enfermedades Metabol Asociadas CIB, Alicante, Spain
[3] Miguel Hernandez Univ Elche, Inst Bioengn, Alicante, Spain
[4] Univ Pisa, Dept Clin & Expt Med, Pisa, Italy
[5] Indiana Univ, Sch Med, Ctr Diabet & Metab Dis, Dept Pediat Med & Physiol, Indianapolis, IN 46204 USA
基金
欧盟地平线“2020”;
关键词
IFN-alpha; JAK inhibitors; MHC class I; Pancreatic beta cells; Pancreatic islets; Type; 1; diabetes; TYPE-1; INTERFERON; APOPTOSIS; STABILITY; CHILDREN;
D O I
10.1007/s00125-017-4536-4
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Aims/hypothesis IFN-alpha, a cytokine expressed in human islets from individuals affected by type 1 diabetes, plays a key role in the pathogenesis of diabetes by upregulating inflammation, endoplasmic reticulum (ER) stress and MHC class I overexpression, three hallmarks of islet histology in early type 1 diabetes. We tested whether expression of these mediators of beta cell loss is reversible upon IFN-alpha withdrawal or IFN-alpha pathway inhibition. Methods IFN-alpha-induced MHC class I overexpression, ER stress and inflammation were evaluated by flow cytometry, immunofluorescence and real-time PCR in human EndoC-beta H1 cells or human islets exposed to IFN-alpha with or without the presence of Janus kinase (JAK) inhibitors. Protein expression was evaluated by western blot. Results IFN-alpha-induced expression of inflammatory and ER stress markers returned to baseline after 24-48 h following cytokine removal. In contrast, MHC class I overexpression at the cell surface persisted for at least 7 days. Treatment with JAK inhibitors, when added with IFN-alpha, prevented MHC class I overexpression, but when added 24 h after IFN-alpha exposure these inhibitors failed to accelerate MHC class I return to baseline. Conclusions/interpretation IFN-alpha mediates a long-lasting and preferential MHC class I overexpression in human beta cells, which is not affected by the subsequent addition of JAK inhibitors. These observations suggest that IFN-alpha-stimulated long-lasting MHC class I expression may amplify beta cell antigen presentation during the early phase of type 1 diabetes and that IFN-alpha inhibitors might need to be used at very early stages of the disease to be effective.
引用
收藏
页码:636 / 640
页数:5
相关论文
共 12 条
  • [1] Inflammation and type one diabetes
    Bending, David
    Zaccone, Paola
    Cooke, Anne
    [J]. INTERNATIONAL IMMUNOLOGY, 2012, 24 (06) : 339 - 346
  • [2] A Type I Interferon Transcriptional Signature Precedes Autoimmunity in Children Genetically at Risk for Type 1 Diabetes
    Ferreira, Ricardo C.
    Guo, Hui
    Coulson, Richard M. R.
    Smyth, Deborah J.
    Pekalski, Marcin L.
    Burren, Oliver S.
    Cutler, Antony J.
    Doecke, James D.
    Flint, Shaun
    McKinney, Eoin F.
    Lyons, Paul A.
    Smith, Kenneth G. C.
    Achenbach, Peter
    Beyerlein, Andreas
    Dunger, David B.
    Clayton, David G.
    Wicker, Linda S.
    Todd, John A.
    Bonifacio, Ezio
    Wallace, Chris
    Ziegler, Anette-G.
    [J]. DIABETES, 2014, 63 (07) : 2538 - 2550
  • [3] FOULIS AK, 1987, LANCET, V2, P1423
  • [4] Freudenburg W., 2013, J CLIN CELL IMMUNOL, V4, P141, DOI [10.4172/2155-9899.1000141, DOI 10.4172/2155-9899.1000141]
  • [5] IFN-γ affects both the stability and the intracellular transport of class I MHC complexes
    Fromm, SV
    Ehrlich, R
    [J]. JOURNAL OF INTERFERON AND CYTOKINE RESEARCH, 2001, 21 (04) : 199 - 208
  • [6] Innate Immune Activity Is Detected Prior to Seroconversion in Children With HLA-Conferred Type 1 Diabetes Susceptibility
    Kallionpaa, Henna
    Elo, Laura L.
    Laajala, Essi
    Mykkanen, Juha
    Ricano-Ponce, Isis
    Vaarma, Matti
    Laajala, Teemu D.
    Hyoty, Heikki
    Ilonen, Jorma
    Veijola, Riitta
    Simell, Tuula
    Wijmenga, Cisca
    Knip, Mikael
    Lahdesmaki, Harri
    Simell, Olli
    Lahesmaa, Riitta
    [J]. DIABETES, 2014, 63 (07) : 2402 - 2414
  • [7] Baricitinib: First Global Approval
    Markham, Anthony
    [J]. DRUGS, 2017, 77 (06) : 697 - 704
  • [8] Interferon-α mediates human beta cell HLA class I overexpression, endoplasmic reticulum stress and apoptosis, three hallmarks of early human type 1 diabetes
    Marroqui, Laura
    Dos Santos, Reinaldo S.
    de Beeck, Anne Op
    de Brachene, Alexandra Coomans
    Marselli, Lorella
    Marchetti, Piero
    Eizirik, Decio L.
    [J]. DIABETOLOGIA, 2017, 60 (04) : 656 - 667
  • [9] TYK2, a Candidate Gene for Type 1 Diabetes, Modulates Apoptosis and the Innate Immune Response in Human Pancreatic β-Cells
    Marroqui, Laura
    Dos Santos, Reinaldo Sousa
    Floyel, Tina
    Grieco, Fabio A.
    Santin, Izortze
    de Beeck, Anne Op
    Marselli, Lorella
    Marchetti, Piero
    Pociot, Flemming
    Eizirik, Decio L.
    [J]. DIABETES, 2015, 64 (11) : 3808 - 3817
  • [10] Islet cell hyperexpression of HLA class I antigens: a defining feature in type 1 diabetes
    Richardson, Sarah J.
    Rodriguez-Calvo, Teresa
    Gerling, Ivan C.
    Mathews, Clayton E.
    Kaddis, John S.
    Russell, Mark A.
    Zeissler, Marie
    Leete, Pia
    Krogvold, Lars
    Dahl-Jorgensen, Knut
    von Herrath, Matthias
    Pugliese, Alberto
    Atkinson, Mark A.
    Morgan, Noel G.
    [J]. DIABETOLOGIA, 2016, 59 (11) : 2448 - 2458